NL-OMON43646已完成不适用
Characterizing the bone marrow environment in advanced-stage myelofibrosis. A PET/MRI study. - BEAMY
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •A diagnosis of primary-, post-polycythemia vera- or post-essential thrombocythemia MF (according to the 2008 WHO criteria)
- •A high- or intermediate-1 or -2 risk level (according to the IWG-MRT DIPSS criteria)
- •Fibrosis (grade 2-4) on bone marrow biopsy
- •A scheduled treatment with (and thus an indication and eligibility for) ruxolitinib
排除标准
- •Current or previous treatment with a JAK2 inhibitor
- •History of allogeneic stem cell transplantation
- •Contraindication for treatment with ruxolitinib (including a platelet count < 50,000/µL)
- •Contraindication for used imaging modalities
- •Inability to sign informed consent
研究者
相似试验
招募中
不适用
Characterizing the bone marrow environment in advanced-stage myelofibrosis. A PET/MRI study.Myelofibrosis. Myelofibrose.Ruxolitinib.PETMRINL-OMON20797VU University Medical Center6
招募中
不适用
Collection of Bone Marrow Aspirate From Normal VolunteersNormal AgingNCT03949647National Institute on Aging (NIA)2,000
Unknown
不适用
Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy ParticipantsLeukemiaMyelodysplastic SyndromesNCT00899327Oxford University Hospitals NHS Trust200
招募中
不适用
Skeletal Health and Bone Marrow Composition in Adolescents With Cystic FibrosisCystic FibrosisNCT06216704Massachusetts General Hospital36
撤回
2 期
Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell TransplantationMyelodysplastic SyndromesMyelofibrosisNCT00148980Hadassah Medical Organization24